June 22, 2022
2 min watch
Save
VIDEO: Novel agent shows promise in thrombocytopenia myelofibrosis
CHICAGO — In a video interview, Aaron Thomas Gerds, MD, MS, discussed the efficacy and safety of momelotinib in a subset of patients with thrombocytopenic myelofibrosis from the MOMENTUM study, which was presented at ASCO Annual Meeting.
“We saw that even when patients were thrombocytopenic, there was still an advantage for momelotinib over danazol,” Gerds, of Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, told Healio.
Published by:
Sources/Disclosures
Collapse
Source:
Gerds AT, et al. Abstract 7061. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Disclosures:
Gerds reports consulting or advising for AbbVie, Bristol-Myers Squibb, Constellation Pharmaceuticals, CTI BioPharma Corp, Novartis, PharmaEssentia and Sierra Oncology.
Read more about